Immunogenicity of a recombinant hepatitis B vaccine in adults

Archives of Internal Medicine

Volumn 156, Issue 19, 1996, Pages 2226-2231

  Bock, Hans L ^b,d   Kruppenbacher, Johannes ^c   Sänger, Roland ^b   Höbel, Wilfried ^b   Clemens, Ralf ^b   Jilg, Wolfgang ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b SmithKline Beecham Pharma   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d SmithKline Beecham Pharma GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; RECOMBINANT VACCINE;

ADULT; AGE; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; FEMALE; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEROLOGY; SEX DIFFERENCE; SMOKING; VACCINATION; VIRUS RECOMBINANT;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; FEMALE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS;

EID: 16044375071     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.156.19.2226     Document Type: Article

References (33)

1. Sherlock S. Hepatitis B: the disease Vaccine 1990;8(suppl):6S-9S.
2. World Health Organization. Prevention of liver cancer: report of a WHO meeting. World Health Organ Tech Rep Ser. 1983;691 1-30.
3. Crosnier J, Jungers P, Couroucé A-M, et al. Randomized placebo-controlled trial of hepatitis B surface antigen vaccine in French hemodialysis units, I. medical staff. Lancet. 1981;1:455-459.
4. Reerink-Brongers EE, Reesink HW, Brummelhuis HGJ, et al. Preparation and evaluation of heat-inactivated HbsAg as a vaccine against hepatitis B. In: Szmuness W, Alter HJ, Maynard JE, eds. Viral Hepatitis. Philadelphia, Pa. Franklin Institute Press; 1982.437-450.
5. Szmuness W, Stevens CE, Harley EJ, et al Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med. 1980;303:833-841.
6. André FE. Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine. Vaccine. 1990;8(suppl):74S-78S
7. Scolnick EM, McLean AA, West DJ, McAleer WJ, Miller WJ, Buynak EB. Clinical evaluation in healthy adults of a hepatitis B vaccine made by recombinant DNA. JAMA. 1984;251:2812-2815.
8. Tron F, Degos F, Bréchot C, et al. Randomized dose range study of a recombinant hepatitis B vaccine produced in mammalian cells and containing the S and preS2 sequences. J Infect Dis. 1989;160.199-204.
9. Wainwright RB, McMahon BJ, Bulkow L, et al Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik Eskimo population. JAMA 1989; 261:2362-2366.
10. Hadler SC, Francis DP, Maynard JE, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men N Engl J Med 1986;315: 209-214.
11. Lo K-J, Lee S-D, Tsai Y-T, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in infants born to HBeAg-positive HBsAg-carrier mothers. Hepatology. 1988;8:1647-1650.
12. Immich H Medizinische Statistik. Stuttgart, Germany Schattauer; 1974:99.
13. Centers for Disease Control. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. MMWR CDC Surveill Summ. 1991,40 1-25.
14. Hess G, Hingst V, Cseke J, Bock HL, Clemens R Influence of vaccination schedules and host factors on antibody response following hepatitis B vaccination. Eur J Clin Microbiol Infect Dis. 1992,11.334-340
15. Dahl-Hansen E, Siebke JC, Frøland SS, Degre M. Immunogenicity of yeast-derived hepatitis B vaccine from two different producers Epidemiol Infect. 1990; 104:143-149.
16. Ginting R, Schilling G, Eis-Hübinger AM, Gerritzen A Hepatitis B vaccines: protective effect and side effects. Arbeitsmed Sozialmed Präventivmed. 1990,25: 517-519.
17. Wood RC, MacDonald KL, White KE, Hedberg CW, Hanson M, Osterholm MT. Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers. JAMA. 1993;270.2935-2939
18. Roome AJ, Walsh SJ, Cartter ML, Hadler JL Hepatitis B vaccine responsiveness in Connecticut public safety personnel JAMA 1993:270:2931-2934.
19. Jilg W, Schmidt M, Deinhardt F. Immune response to late booster doses of hepatitis B vaccine J Med Virol. 1985;17:249-254.
20. Hadler SC, Monson MA, Lugo DR, Perez M. Effect of timing of hepatitis B vaccine dose on response to vaccine in Yucpa Indians. Vaccine 1989,7:106-110.
21. Mangione R, Stroffolini T, Tosti ME, Fragapani D, Mele A Delayed third hepatitis B vaccine dose and immune response. Lancet. 1995;345:1111-1112
22. Lau JYN, Lai CL, Wu PC, Lin HJ. Comparison of two plasma-derived hepatitis B vaccines: long-term report of a prospective, randomized trial. J Gastroenterol Hepatol 1989,4:331-337.
23. Weber DJ, Rutala WA, Samsa GP, Santimaw JE, Lemon SM Obesity as a predictor of poor immune response to hepatitis B plasma vaccine JAMA. 1985; 254:3187-3189.
24. Winter AP, Follett EAC, McIntyre J, Stewart J, Symington IS. Influence of smoking on immunological responses to hepatitis B vaccine Vaccine. 1994;12:771-772
25. Corrao G, Calleri M, Zotti M, et al. Immune response to anti-HBV vaccination: study of conditioning factors. Eur J Epidemiol. 1988;4.492-496.
26. Novicki MJ, Tong MJ, Bohmann RE. Alterations in the immune response of nonresponders to the hepatitis B vaccine. J Infect Dis. 1985,152:1245-1248.
27. Centers for Disease Control. Protection against viral hepatitis - recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR CDC Surveill Summ. 1990,39.1-26.
28. Hadler SC, Francis DP, Maynard JE, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men N Engl J Med. 1986:315:209-214
29. Szmuness W, Stevens CE, Zang EA, Harley EJ, Kellner A A controlled trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology. 1981;1:377-385.
30. Goudeau A, Coursaget P, Barin F, et al. Prevention of hepatitis B by active and passive-active immunization. In: Szmuness W, Alter HJ, Maynard JE. eds Viral Hepatitis Philadelphia, Pa: Franklin Institute Press; 1982 509-525.
31. Gesemann M, Scheiermann N. Quantification of hepatitis B vaccine - induced antibodies as a predictor of anti-HBs persistence. Vaccine 1995;13:443-447.
32. Bouter KP, Diepersloot RJA, Wismans PJ, et al. Humoral immune response to a yeast-derived hepatitis B vaccine in patients with type I diabetes mellitus. Diabet Med 1992;9:66-69
33. Couroucé-Pauty AM, Naret C, Ciancionnoni C, Adhemar JP, Soulier JP. Prevention of viral hepatitis B in haemodiaiysis units by means of anti-HBs immunoglobulins In: Touraine JL, Traeger J, Bétuel H, et al, eds. Transplantation and Clinical Immunology. Amsterdam, the Netherlands: Excerpta Medica; 1979 77-85.